Methods for improved therapeutic use of recombinant AAV
AssigneeUltragenyx Pharmaceutical Inc.
InventorsBarbara Anne Sullivan, Kathleen Phillips Mckeever
Life of this patent
Estimating the term…
Abstract
Provided herein are methods for managing host immune responses to improve therapeutic outcomes in adeno-associated virus (AAV)-mediated gene therapy. Such methods may include administering a recombinant adeno-associated vims (rAAV) to a subject following administration of a CD 19 inhibitor, e.g., an anti-CD 19 antibody. The methods described herein can facilitate improved transgene expression, help overcome pre-existing NAbs, and/or permit redosing with the same or substantially similar rAAV or transgene.
Claims20
A method of managing an immune response against a recombinant adeno-associated virus (rAAV) administered to a subject, the method comprising:
- (a) administering a CD19 inhibitor to said subject and (b) subsequently administering the rAAV to said subject.
Dependencies are inferred from the claim text.